September 10, 2025Frontiers in MedicineOpen Access

Efficacy and health economics of Bufei Yishen granules in patients with frequent exacerbator phenotype in the stable phase of chronic obstructive pulmonary disease: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

View Full Paper

Ask AI

Bookmark

Bufei Yishen granules may reduce AECOPD frequency in chronic obstructive pulmonary disease patients, ultimately improving health outcomes.
The trial assesses primary outcomes like AECOPD frequency and secondary outcomes such as hospitalization rates and quality of life.
Conducting a multicenter, randomized, double-blind trial involving 848 patients over one year ensures reliable data on treatment effectiveness.
The study's health economics assessment aims to evaluate the cost-effectiveness of Bufei Yishen granules compared to standard treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Multicenter RCT assesses Bufei Yishen granules' impact on AECOPD in frequent exacerbators, suggesting potential improvements in lung function.

Xiao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Multicenter RCT assesses Bufei Yishen granules' impact on AECOPD in frequent exacerbators, suggesting potential improvements in lung function.